| FDA | U.S. Food and Drug Administration |
| CDER | The Center for Drug Evaluation and Research |
| CBER | The Center for Biologics Evaluation and Research |
| WHO | World health organization |
| mAb | Monoclonal antibody |
| bsAb | Bispecific antibody |
| ADC | Antibody drug conjugate |
| CAR T | Chimeric antigen receptor T cell |
| TNF | Tumor necrosis factor |
| GPCR | G-protein coupled receptor |
| GLP-1 | Glucagon-like peptide-1 |
| GIP | Glucose-dependent insulinotropic polypeptide |
| AAV | Adeno-associated virus |
| GM-CSF | Granulocyte-macrophage colony stimulating factor |
| ON | Oligonucleotide |
| ASO | Antisense oligonucleotide |
| siRNA | Short interfering RNA |
| GalNac | N-acetylgalactosamine |
| CRISPR | Clustered regularly interspaced short palindromic repeats |
| T1D | Type 1 diabetes mellitus |
| T2D | Type 2 diabetes mellitus |
| HbA1c | Hemoglobin A1c |
| HSC | Hematopoietic stem cell |
| MSC | Mesenchymal stem cell |
| NF-κB | Nuclear factor -κB |
| JAK | Janus kinase |
| STAT | Transducer and activator of transcription |
| SYK | Spleen tyrosine kinase |
| TYK2 | Tyrosine kinase 2 |
| BTK | Bruton’s tyrosine kinase |
| AtD | Atopic dermatitis |
| Th | T helper |
| PDE4 | Phosphodiesterase 4 |
| EASI | Eczema area and severity index |
| H4R | Histamine H4 receptor |
| MAdCAM | Mucosal addressin cell adhesion molecule |
| S1P | Sphingosine 1-phosphate |
| CNS | Central nervous system |
| OA | Osteoarthritis |
| NSAID | Nonsteroidal anti-inflammatory drug |
| COX | Cyclooxygenase |
| NGF | Nerve growth factor |
| MMP | Matrix metalloproteinase |
| CGRP | Calcitonin gene-related peptide |
| ND | Neurodegenerative disease |
| AD | Alzheimer’s disease |
| PD | Parkinson’s disease |
| AChEIs | Acetylcholinesterase inhibitors |
| NMDA | N-methyl-D-aspartic acid |
| DMTs | Disease-modifying treatments |